Business
Avicanna to Supply UK Market with Cannabis-Based Medicinal Products Through Distribution Agreement with the LYPHE Group
Avicanna to Supply UK Market with Cannabis-Based Medicinal Products Through Distribution A...
About this update from Avicanna Inc
[{"type":"text","content":"\n\n\n\nAvicanna to Supply UK Market with Cannabis-Based Medicinal Products Through Distribution Agreement with the LYPHE Group\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Dec. 3, 2019\n\n\n\n/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS./\n TORONTO, Dec. 3, 2019 /CNW/ - Avicanna Inc. (\"Avicanna\" or the \"Company\") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into an importation and distribution agreement (the \"Agreement\") with Astral Health Ltd. (\"Astral\"), the operating subsidiary of the LYPHE Group Ltd (\"LYPHE Group\" or \"LYPHE\") to supply its cannabis-based medicinal products (\"CBMPs\") to patients in the United Kingdom under the MHRA 'specials' programme.\n\n \n \n\n \n\"We look forward to the opportunity to provide access to our cannabis-based medicinal formulations to a population and medical community that is seeing increased demand for quality evidence-based products, such as our proprietary research-backed formulations. Both the Astral and Avicanna teams are aligned on the long-term vision and more importantly are qualified to provide the medical community in the United Kingdom with safe, effective and superior cannabinoid-based solutions, education and training,\" stated Aras Azadian, Chief Executive Officer. \nDean Friday, Chief Executive Officer of LYPHE, commented \"We are very proud to be partnering with Avicanna in bringing their products to the UK market.  Avicanna are market-leaders in terms of product quality, and their research-backed formulations give the company a distinct advantage in the UK market\".\nUnder the Agreement, Avicanna will supply Astral with CBMPs, and both Avicanna and Astral will work together to achieve key strategic...